Find a clinical trial

FindClinicalTrial

If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

« Previous 1234 Next »
Viewing Page 1 of 4 | Showing Results 1 - 5 of 18

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756)

Inclusion Criteria:•Has a localized invasive breast ductal adenocarcinoma, confirmed by the local pathologist, that includes either T1c-T2 (tumor...

Ying Zhuo, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

This randomized phase III trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib when given in...

Rangaswamy Chintapatla, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Inclusion criteria:1.Histologically or cytologically documented limited-stage small cell lung cancer (stage I-III).2.Received 4 cycles of...

Basir Haque, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

Stroke-Related Early Tracheostomy Versus Prolonged Orotracheal Intubation in Neurocritical Care Trial 2

Inclusion Criteria:Age 18 years or olderinformed consent from legal representativenon-traumatic cerebrovascular diseaseEstimated ventilation need...

Phani Kantamneni, M.D.
  • Kadlec Regional Medical Center
  • Kadlec Research
« Previous 1234 Next »
Viewing Page 1 of 4 | Showing Results 1 - 5 of 18